Camptosar
(irinotecan hydrochloride)ApprovedSmall molecule
PfizerIrinotecan is a chemotherapy drug used to treat certain types of cancer, particularly colorectal cancer and sometimes lung or ovarian cancer. It works by damaging cancer cells' DNA to stop them from growing and dividing.[2] Camptosar is currently approved and in use across 17 indications[4].[1]
Camptosar is one of 328 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Approved.
17
Indications
323
Total Trials
9
Active Trials
327
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 17 indications
Competition
Competitive Landscape
335 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Camptosar
PfizerApproved
Byetta
AstraZenecaPreclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Active Comparator
ModernaPreclinical
Sulfonylureas
Eli LillyPreclinical
Hyperpolarized 13c Pyruvate
UUniversity of Maryland, Baltimore
Preclinical
PEG-Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Colorectal Cancer35 trials
Show 32 more trials
Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer
Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT00003260·109 enrolled
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
Terminated·—·Phase 2·NCT02508077·1 enrolled
Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer
Completed·—·Phase 2·NCT01205711·111 enrolled
Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
Completed·—·Phase 4·NCT00559676·200 enrolled
Colorectal Cancer17 trials
Show 14 more trials
Patients With Advanced Solid Tumors11 trials
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Completed·—·Phase 1·NCT00006465·22 enrolled
UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00047242·30 enrolled
Show 8 more trials
Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT00003710·12 enrolled
Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors
Completed·—·Phase 1·NCT00002902
Pancreatic Cancer10 trials
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
Terminated·—·Phase 2·NCT01897454·23 enrolled
Show 7 more trials
Small Cell Lung Cancer10 trials
Show 7 more trials
64 more indications
Non-Small Cell Lung Cancer9 trials
Show 6 more trials
Breast Cancer7 trials
Esophageal Cancer7 trials
Neuroblastoma5 trials
N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma
Completed·—·Phase 1·NCT00509353·26 enrolled
Show 2 more trials
Refractory Solid Tumors4 trials
Glioblastoma Multiforme4 trials
Patients With Solid Tumors4 trials
Show 1 more trial
Intestinal Cancer3 trials
Radiation Therapy3 trials
Glioma3 trials
Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
Completed·—·Phase 1·NCT00003463
Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas
Completed·—·Phase 2·NCT00268359·68 enrolled
Locally Advanced or Metastatic Solid Tumors3 trials
Rhabdomyosarcoma3 trials
Malignant Glioma3 trials
Unresectable Solid Tumor2 trials
Metastatic Solid Tumors2 trials
Lymphoma2 trials
Stage III Colon Cancer2 trials
Soft Tissue Sarcoma2 trials
Kidney Cancer2 trials
Solid Tumors2 trials
Advanced Solid Tumors2 trials
Bladder Cancer1 trial
Gastric Cancer1 trial
Cancer of the Esophagus1 trial
Locally-advanced Rectal Cancer1 trial
Locally Advanced1 trial
S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer
Unknown status·—·Phase 2·NCT00134095·70 enrolled
Peritoneal Cancer1 trial
Primary Brain Tumor1 trial
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
Completed·—·Phase 1·NCT00003484·21 enrolled
Solid Tumor Malignancies1 trial
Recurrent Hepatoblastoma1 trial
Stomach Cancer1 trial
Stage II Colon Cancer1 trial
Diarrhea1 trial
HER2-Positive Solid Tumor1 trial
Glioblastoma1 trial
Radiosurgery Plus Bevacizumab in Glioblastoma
Terminated·—·Phase 1·NCT01086345·9 enrolled
Gastroesophageal Junction Carcinoma1 trial
Small Bowel Cancer1 trial
Low Grade Glioma1 trial
Ewing sarcoma1 trial
Refractory or Recurrent Solid Tumor1 trial
Bile Duct Cancer1 trial
Biliary Tract Cancer1 trial
Colon Cancer1 trial
Gastrointestinal1 trial
Metastatic1 trial
Metastatic Cancer1 trial
First Line Therapy1 trial
Penile Cancer1 trial
Cancer of the Pancreas1 trial
Advanced Malignancies1 trial
Pancreatic Adenocarcinoma1 trial
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
Terminated·—·Phase 2·NCT02345460·1 enrolled
Locally Advanced Cancer1 trial
Colorectal Carcinoma1 trial
Regulatory
FDA Approval Timeline[5]
Jun 14, 1996
CAMPTOSAR
NDA NDA020571
Oct 22, 2015
ONIVYDE
NDA NDA207793
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Camptosar drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for irinotecan hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]